Guggenheim reiterated a Buy on Neurocrine Biosciences, Inc. (NASDAQ:NBIX) and lifted its price target to $200, while the company promoted Samir Siddhanti to Chief Business Officer to drive growth, BD, corporate strategy and maximize pipeline value.
Previous Week Recap
- Guggenheim Raises NBIX Target: Guggenheim kept a Buy on Neurocrine Biosciences (NBIX) and raised its price target from $175 to $200 per share — a higher valuation point for NBIX.
- Samir Siddhanti Named CBO: Neurocrine Biosciences (NBIX) named Samir Siddhanti Chief Business Officer to lead growth, business development, corporate strategy, alliance and program management to maximize pipeline value
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original sources.